Ivantis, Inc. Overview
Pro stress-test →Ivantis was a privately-held medical device company headquartered in Irvine, California, specializing in minimally invasive glaucoma surgery (MIGS) solutions. Founded in 2007, the company developed and commercialized the Hydrus Microstent, a novel surgical device designed to lower intraocular pressure for glaucoma patients. Ivantis was acquired by Alcon, a global eye-care leader, in January 2022 for $475 million.
Strategic Profile
Pro stress-test →Ivantis positioned itself in the high-growth MIGS segment of ophthalmology, targeting surgeons and patients seeking less invasive alternatives to traditional glaucoma procedures. The Hydrus Microstent technology was FDA-approved in August 2018 and represented a differentiated approach to surgical glaucoma management. The Alcon acquisition integrated Ivantis into a larger global ophthalmology portfolio, enabling broader market reach and patient access.
Competitive Landscape
Pro stress-test →Before acquisition, Ivantis competed in the MIGS device market against companies including Glaukos, Sight Sciences, iSTAR Medical, Avisi Technologies, Myra Vision, and Implandata Ophthalmic Products. The MIGS space has experienced significant innovation and consolidation, with multiple competitors pursuing minimally invasive glaucoma surgical solutions to address the growing unmet need for effective, less-invasive treatments.
Industry Context
Ivantis, Inc. operates in Minimally invasive glaucoma surgery (MIGS) devices.
Key facts
Founded: 2007 · Headquarters: Irvine, US · Employees: 145 · Revenue: N/A · Market cap: N/A - Acquired subsidiary